Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E. van Hall T, et al. Among authors: andre p. J Immunother Cancer. 2019 Oct 17;7(1):263. doi: 10.1186/s40425-019-0761-3. J Immunother Cancer. 2019. PMID: 31623687 Free PMC article. Review.
NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T. van Montfoort N, et al. Among authors: andre p. Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29. Cell. 2018. PMID: 30503208 Free PMC article.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. André P, et al. Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Targeting natural killer cells in solid tumors.
Habif G, Crinier A, André P, Vivier E, Narni-Mancinelli E. Habif G, et al. Among authors: andre p. Cell Mol Immunol. 2019 May;16(5):415-422. doi: 10.1038/s41423-019-0224-2. Epub 2019 Mar 25. Cell Mol Immunol. 2019. PMID: 30911118 Free PMC article. Review.
[Natural killer cells: promising targets in cancer therapy].
Cornen S, André P, Gauthier L, Morel Y, Vivier É. Cornen S, et al. Among authors: andre p. Med Sci (Paris). 2019 Dec;35(12):990-992. doi: 10.1051/medsci/2019195. Epub 2020 Jan 6. Med Sci (Paris). 2019. PMID: 31903904 Free article. Review. French.
Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.
Romagné F, André P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Della Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N. Romagné F, et al. Among authors: andre p. Blood. 2009 Sep 24;114(13):2667-77. doi: 10.1182/blood-2009-02-206532. Epub 2009 Jun 24. Blood. 2009. PMID: 19553639 Free PMC article.
849 results